CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
RAD001 +1 moredrug
Likely dose
RAD001 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01031381
NCT01031381Phase 2Completed
CompareCT.gov

Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital

University of Pittsburgh·interventional·Posted Dec 14, 2009·Updated Aug 30, 2016

In Brief

A Phase 2 clinical trial evaluating RAD001 and bevacizumab for Ovarian Cancer and 2 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study will investigate the efficacy as well as the safety of RAD001 in combination with bevacizumab for recurrent ovarian, peritoneal, and fallopian tube cancer. RAD001 will be taken orally once daily and bevacizumab will be administered once every 14 days. The study will be conducted over a period of about 3 to 4 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 14, 2009
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.6 years ago

Interventions

RAD001drug

RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.

bevacizumabdrug

bevacizumab will be administered intravenously (IV) once every 14 days.